Current posture

What matters now

Sangamo is in an active Chapter 11 sale process, with proposed stalking-horse asset sales facing limited objections from Astellas and Alexion and a separate Roche/Genentech request concerning a sale objection and a § 365(n) election. The immediate case focus is therefore the disposition of the debtor's technology and program assets, while the Official Committee of Unsecured Creditors is represented by court-approved counsel effective July 2. Committee-counsel retention order Dkt. 293 Sangamo filed its voluntary Chapter 11 petition Dkt. 1 in Delaware on June 23, 2026, after a steep revenue decline, substantial multi-year net losses, the termination of a major Pfizer collaboration, and a constrained biotech-financing market, as described in its first-day declaration Dkt. 2. The debtor entered the case with no funded debt and pursued a Section 363 process for distinct asset packages, including stalking-horse arrangements for its Fabry disease program and neurological technology platform, supported initially by proposed DIP financing. First-day declaration Dkt. 2 The sale path now carries counterparty and intellectual-property issues: Astellas and Alexion each lodged limited objections to a proposed free-and-clear sale to a stalking horse…

Updated Aug 18, 2026

Material case activity

1. Sangamo Therapeutics wins court approval for three sales

   Aug 20, 2026

   A Delaware bankruptcy judge approved three Sangamo Therapeutics sales expected to generate $52 million in cash after the company’s Chapter 11 auction produced four winning bids valued at more than $238 million.